PSNLPersonalis Inc
$11.49
$1.30
(12.92%)
Closed $11.36
$0.1287
(1.13%)
After Hours
EarningsAug 5
Mkt Cap$1.05B
Vol5.95M
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Unions In Vitro Diagnostic Regulation...
Business Wire
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?
Key PointsCEO Christopher Hall sold 100,000 shares across May 28 and May 29, 2026, for a transaction value of ~$1.10 million at a weighted average price around $11.02 per share...
Nasdaq News: Markets
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer...
Business Wire
Personalis to Highlight Breadth of NeXT Personal Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that six clinical abstracts demonstrating the broad use of its NeXT Personal test will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 to...
Business Wire
US Agency Broadens Coverage Of Personalis Breast Cancer Test
Personalis wins expanded Medicare coverage for NeXT Personal MRD test in breast cancer patients undergoing neoadjuvant therapy.read more...
Benzinga
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the companys NeXT Personal minimal residual disease (MRD) test. The...
Business Wire
Personalis to Participate in Upcoming Investor Events
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the following investor events: Craig Hallum...
Business Wire
Personalis Receives Medicare Coverage for NeXT Personal for Immunotherapy Monitoring Across Late-stage Solid Tumors
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostic Services Program...
Business Wire
Personalis (PSNL) Q1 2026 Earnings Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of -26.09% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>
Advertisement|Remove ads.
Latest PSNL News
ViewPersonalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
Business Wire
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?
Nasdaq News: Markets
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Business Wire
Advertisement|Remove ads.